Idexx Laboratories Stock Net Asset
| IDXX Stock | USD 499.30 10.06 2.06% |
IDEXX Laboratories fundamentals help investors to digest information that contributes to IDEXX Laboratories' financial success or failures. It also enables traders to predict the movement of IDEXX Stock. The fundamental analysis module provides a way to measure IDEXX Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IDEXX Laboratories stock.
IDEXX | Net Asset |
IDEXX Laboratories Company Net Asset Analysis
IDEXX Laboratories' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current IDEXX Laboratories Net Asset | 3.26 B |
Most of IDEXX Laboratories' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IDEXX Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
IDEXX Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for IDEXX Laboratories is extremely important. It helps to project a fair market value of IDEXX Stock properly, considering its historical fundamentals such as Net Asset. Since IDEXX Laboratories' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IDEXX Laboratories' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IDEXX Laboratories' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
IDEXX Total Assets
Total Assets |
|
Based on the recorded statements, IDEXX Laboratories has a Net Asset of 3.26 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
IDEXX Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IDEXX Laboratories' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IDEXX Laboratories could also be used in its relative valuation, which is a method of valuing IDEXX Laboratories by comparing valuation metrics of similar companies.IDEXX Laboratories is currently under evaluation in net asset category among related companies.
IDEXX Laboratories ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, IDEXX Laboratories' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to IDEXX Laboratories' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
IDEXX Laboratories Institutional Holders
Institutional Holdings refers to the ownership stake in IDEXX Laboratories that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of IDEXX Laboratories' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing IDEXX Laboratories' value.| Shares | Brown Advisory Holdings Inc | 2023-12-31 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.1 M | Capital World Investors | 2023-12-31 | 1 M | Norges Bank | 2023-12-31 | 922.8 K | Northern Trust Corp | 2023-12-31 | 862.6 K | Jpmorgan Chase & Co | 2023-12-31 | 860.5 K | Fundsmith Investment Services Ltd. | 2023-12-31 | 818.6 K | Legal & General Group Plc | 2023-12-31 | 787.2 K | Principal Financial Group Inc | 2023-12-31 | 781.4 K | Blackrock Inc | 2023-12-31 | 9.1 M | Vanguard Group Inc | 2023-12-31 | 8.4 M |
IDEXX Fundamentals
| Return On Equity | 0.81 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 42.1 B | ||||
| Shares Outstanding | 83.05 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 92.19 % | ||||
| Number Of Shares Shorted | 1.71 M | ||||
| Price To Earning | 61.31 X | ||||
| Price To Book | 27.85 X | ||||
| Price To Sales | 11.29 X | ||||
| Revenue | 3.66 B | ||||
| Gross Profit | 2 B | ||||
| EBITDA | 1.1 B | ||||
| Net Income | 845.04 M | ||||
| Cash And Equivalents | 114.36 M | ||||
| Cash Per Share | 1.37 X | ||||
| Total Debt | 947.88 M | ||||
| Debt To Equity | 3.27 % | ||||
| Current Ratio | 0.89 X | ||||
| Book Value Per Share | 17.88 X | ||||
| Cash Flow From Operations | 906.51 M | ||||
| Short Ratio | 4.26 X | ||||
| Earnings Per Share | 10.04 X | ||||
| Price To Earnings To Growth | 4.75 X | ||||
| Target Price | 604.62 | ||||
| Number Of Employees | 11 K | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 41.47 B | ||||
| Total Asset | 3.26 B | ||||
| Retained Earnings | 4.44 B | ||||
| Working Capital | 543.71 M | ||||
| Current Asset | 821.63 M | ||||
| Current Liabilities | 856.76 M | ||||
| Net Asset | 3.26 B |
About IDEXX Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IDEXX Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IDEXX Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IDEXX Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out IDEXX Laboratories Piotroski F Score and IDEXX Laboratories Altman Z Score analysis. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.121 | Earnings Share 10.04 | Revenue Per Share 44.073 | Quarterly Revenue Growth 0.088 | Return On Assets 0.2283 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.